uniQure (QURE) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $22.52, +7.39% vs the prior close of $20.97.
- Volume 1.61M shares, 0.7x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
QURE jumps 7.4% to $22.52. Closed at $22.52, +7.39% vs the prior close of $20.97. Day range $20.76–$22.56, opened at $21.94.
QURE daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — QURE jumps 7.4% to $22.52
- Closed at $22.52, +7.39% vs the prior close of $20.97. Day range $20.76–$22.56, opened at $21.94.
- Volume was 1.61M shares, 0.7x its 50-day average of 2.18M.
- Price is -43.4% vs its 50-day average ($39.77) and -24.0% vs its 200-day average ($29.65).
- 52-week range $8.73–$71.50; today's close sits at 22% of that range, 68.5% below the 52-week high.
Oct 14, 2026 — QURE dips 1.5% to $20.97, a 3-month low, 3 down days in a row
- Closed at $20.97, -1.46% vs the prior close of $21.28. Day range $20.33–$21.75, opened at $21.00.
- Volume was 3.32M shares, 1.6x its 50-day average of 2.14M.
- Price is -47.8% vs its 50-day average ($40.20) and -29.3% vs its 200-day average ($29.66).
- 52-week range $8.73–$71.50; today's close sits at 19% of that range, 70.7% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — QURE dips 2.6% to $21.28, a 3-month low
- Closed at $21.28, -2.56% vs the prior close of $21.84. Day range $20.75–$21.66, opened at $21.66.
- Volume was 2.49M shares, 1.2x its 50-day average of 2.11M.
- Price is -47.7% vs its 50-day average ($40.66) and -28.3% vs its 200-day average ($29.67).
- 52-week range $8.73–$71.50; today's close sits at 20% of that range, 70.2% below the 52-week high.
Oct 12, 2026 — QURE slides 3.3% to $21.84, a 3-month low
- Closed at $21.84, -3.32% vs the prior close of $22.59. Day range $21.49–$22.59, opened at $22.38.
- Volume was 1.41M shares, 0.7x its 50-day average of 2.11M.
- Price is -46.9% vs its 50-day average ($41.11) and -26.5% vs its 200-day average ($29.69).
- 52-week range $8.73–$71.50; today's close sits at 21% of that range, 69.5% below the 52-week high.
Oct 9, 2026 — QURE ends flat (+0.2%) to $22.59
- Closed at $22.59, +0.22% vs the prior close of $22.54. Day range $22.23–$23.00, opened at $22.59.
- Volume was 2.05M shares, 1.0x its 50-day average of 2.11M.
- Price is -45.6% vs its 50-day average ($41.55) and -24.0% vs its 200-day average ($29.71).
- 52-week range $8.73–$71.50; today's close sits at 22% of that range, 68.4% below the 52-week high.
Oct 8, 2026 — QURE dips 2.6% to $22.54, a 3-month low
- Closed at $22.54, -2.59% vs the prior close of $23.14. Day range $21.70–$23.00, opened at $22.92.
- Volume was 1.82M shares, 0.8x its 50-day average of 2.15M.
- Price is -46.3% vs its 50-day average ($41.94) and -24.2% vs its 200-day average ($29.72).
- 52-week range $8.73–$71.50; today's close sits at 22% of that range, 68.5% below the 52-week high.
Oct 7, 2026 — QURE rises 0.3% to $23.14
- Closed at $23.14, +0.35% vs the prior close of $23.06. Day range $22.62–$23.30, opened at $22.96.
- Volume was 1.78M shares, 0.8x its 50-day average of 2.18M.
- Price is -45.3% vs its 50-day average ($42.29) and -22.2% vs its 200-day average ($29.73).
- 52-week range $8.73–$71.50; today's close sits at 23% of that range, 67.6% below the 52-week high.
Oct 6, 2026 — QURE rises 1.1% to $23.06
- Closed at $23.06, +1.14% vs the prior close of $22.80. Day range $21.20–$23.84, opened at $23.02.
- Volume was 2.82M shares, 1.3x its 50-day average of 2.15M.
- Price is -45.8% vs its 50-day average ($42.56) and -22.4% vs its 200-day average ($29.73).
- 52-week range $8.73–$71.50; today's close sits at 23% of that range, 67.7% below the 52-week high.
Oct 5, 2026 — QURE dips 2.8% to $22.80, a 3-month low
- Closed at $22.80, -2.81% vs the prior close of $23.46. Day range $21.37–$23.24, opened at $22.28.
- Volume was 3.04M shares, 1.4x its 50-day average of 2.12M.
- Price is -46.8% vs its 50-day average ($42.86) and -23.3% vs its 200-day average ($29.73).
- 52-week range $8.73–$71.50; today's close sits at 22% of that range, 68.1% below the 52-week high.
Oct 2, 2026 — QURE rises 0.4% to $23.46
- Closed at $23.46, +0.39% vs the prior close of $23.37. Day range $22.71–$23.72, opened at $23.72.
- Volume was 1.95M shares, 0.9x its 50-day average of 2.09M.
- Price is -45.7% vs its 50-day average ($43.19) and -21.1% vs its 200-day average ($29.72).
- 52-week range $8.73–$71.50; today's close sits at 23% of that range, 67.2% below the 52-week high.
QURE latest news & SEC filings
Every SEC filing by or about QURE in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 2, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 29, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Jul 29, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Key figures from this report aren't in the SEC's structured data yet (usually appears within a day or two).
Jul 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 20, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 16, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Kapusta Matthew C sold 7,600 shares at $45.89 (≈$348.76K) on Jul 2, 2026
- Kapusta Matthew C sold 4,282 shares at $45.43 (≈$194.53K) on Jul 2, 2026
- Kapusta Matthew C sold 9,200 shares at $44.43 (≈$408.76K) on Jul 2, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Abi-Saab Walid sold 20,000 shares at $46.40 (≈$928.00K) on Jun 30, 2026
- Abi-Saab Walid sold 10,000 shares at $46.46 (≈$464.60K) on Jun 30, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Kaye Jack sold 17,060 shares at $46.43 (≈$792.10K) on Jun 30, 2026
- Kaye Jack sold 4,107 shares at $46.49 (≈$190.93K) on Jun 30, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 2, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jun 30, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Abi-Saab Walid sold 1,434 shares at $46.86 (≈$67.20K) on Jun 26, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jun 30, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Things to know before you trade QURE
- Last results release: Jul 29, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Mar 2, 2026, Nov 10, 2025. Based on that rhythm, the next report is likely around Oct 28, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.29% (largest 37.3%). That is a volatile stock.
- Liquidity: about 3.76M shares (≈$84.69M) trade per day on average.
- 52-week position: $22.52 vs a range of $8.73–$71.50 (22% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Matthew C Kapusta sold 7,600 shares on Jul 2, 2026.
- Latest filings: 8-K Sep 29, 2026; 8-K Sep 2, 2026; 10-Q Jul 29, 2026.
- Share count: 63.07M shares outstanding (May 1, 2026), +15.2% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
QURE market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 21.94 | 22.56 | 20.76 | 22.52 | 1.61M |
| Oct 14, 2026 | 21.00 | 21.75 | 20.33 | 20.97 | 3.32M |
| Oct 13, 2026 | 21.66 | 21.66 | 20.75 | 21.28 | 2.49M |
| Oct 12, 2026 | 22.38 | 22.59 | 21.49 | 21.84 | 1.41M |
| Oct 9, 2026 | 22.59 | 23.00 | 22.23 | 22.59 | 2.05M |
| Oct 8, 2026 | 22.92 | 23.00 | 21.70 | 22.54 | 1.82M |
| Oct 7, 2026 | 22.96 | 23.30 | 22.62 | 23.14 | 1.78M |
| Oct 6, 2026 | 23.02 | 23.84 | 21.20 | 23.06 | 2.82M |
| Oct 5, 2026 | 22.28 | 23.24 | 21.37 | 22.80 | 3.04M |
| Oct 2, 2026 | 23.72 | 23.72 | 22.71 | 23.46 | 1.95M |
| Oct 1, 2026 | 24.34 | 24.90 | 23.24 | 23.37 | 3.18M |
| Sep 30, 2026 | 25.07 | 26.68 | 24.01 | 24.16 | 7.44M |
| Sep 29, 2026 | 23.85 | 26.00 | 22.47 | 24.51 | 29.81M |
| Sep 28, 2026 | 37.65 | 39.67 | 37.18 | 39.11 | 1.85M |
| Sep 25, 2026 | 38.19 | 39.12 | 37.62 | 38.23 | 1.17M |
| Sep 24, 2026 | 42.42 | 42.87 | 36.82 | 38.32 | 4.24M |
| Sep 23, 2026 | 45.17 | 45.41 | 42.62 | 42.76 | 1.17M |
| Sep 22, 2026 | 44.50 | 45.80 | 44.47 | 45.28 | 1.14M |
| Sep 21, 2026 | 44.50 | 45.03 | 43.81 | 44.31 | 801.20K |
| Sep 18, 2026 | 44.40 | 44.52 | 43.56 | 44.00 | 2.10M |
About uniQure
uniQure (QURE) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in AMSTERDAM. Fiscal year ends December 31. SEC CIK 1590560.
QURE board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Madhavan Balachandran | Director | Jun 22, 2026 |
| Robert Gut | Director | Jun 12, 2026 |
| Rachelle Suzanne Jacques | Director | Jun 12, 2026 |
| Matthew C Kapusta | CEO, Managing Director | Jul 7, 2026 |
| Jack Kaye | Director | Jul 2, 2026 |
| David D. Meek | Director | Jun 12, 2026 |
| Leonard E Post | Director | Jun 12, 2026 |
| Jeremy P. Springhorn | Director | Jun 12, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Walid Abi-Saab | Chief Medical Officer | Jul 2, 2026 |
| Christian Klemt | Chief Financial Officer | Mar 6, 2026 |
| Matthew C Kapusta | CEO, Managing Director | Jul 7, 2026 |
| Kylie O'Keefe | Chief Customer & Strat Officer | Jun 12, 2026 |
| Jeannette Potts | Chief Legal Officer | Jun 17, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 2, 2026 | Matthew C Kapusta | Sale | 7,600 | $45.89 |
| Jul 2, 2026 | Matthew C Kapusta | Sale | 4,282 | $45.43 |
| Jul 2, 2026 | Matthew C Kapusta | Sale | 9,200 | $44.43 |
| Jun 30, 2026 | Jack Kaye | Sale | 17,060 | $46.43 |
| Jun 30, 2026 | Jack Kaye | Sale | 4,107 | $46.49 |
| Jun 30, 2026 | Walid Abi-Saab | Sale | 20,000 | $46.40 |
| Jun 30, 2026 | Walid Abi-Saab | Sale | 10,000 | $46.46 |
| Jun 26, 2026 | Walid Abi-Saab | Sale | 1,434 | $46.86 |
| Jun 25, 2026 | Matthew C Kapusta | Sale | 28,716 | $50.02 |
| Jun 24, 2026 | Matthew C Kapusta | Sale | 6,696 | $50.00 |
| Jun 18, 2026 | Matthew C Kapusta | Sale | 37,015 | $50.00 |
| Jun 18, 2026 | Matthew C Kapusta | Sale | 4,656 | $50.00 |
| Jun 17, 2026 | Madhavan Balachandran | Sale | 1,690 | $42.60 |
| Jun 17, 2026 | Madhavan Balachandran | Sale | 4,700 | $43.66 |
| Jun 17, 2026 | Madhavan Balachandran | Sale | 5,295 | $47.08 |
QURE financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-198.97M | -3.46 | $-177.96M |
| Dec 31, 2024 | — | $-239.56M | -4.92 | $-182.73M |
| Dec 31, 2023 | — | $-308.48M | -6.47 | $-145.93M |
| Dec 31, 2017 | $13.11M | — | — | — |
| Dec 31, 2016 | $25.10M | — | — | — |
Latest balance sheet: total assets $778.71M, total liabilities $629.36M, cash $139.99M (as of Mar 31, 2026).
QURE earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 29, 2026 | 8-K Item 2.02 (results) | $40.07 |
| May 5, 2026 | 8-K Item 2.02 (results) | $21.16 |
| Mar 2, 2026 | 8-K Item 2.02 (results) | $10.50 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $26.15 |
| Jul 29, 2025 | 8-K Item 2.02 (results) | $13.68 |
| May 9, 2025 | 8-K Item 2.02 (results) | $12.79 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $12.07 |
| Nov 5, 2024 | 8-K Item 2.02 (results) | $6.06 |
| Aug 1, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
| Feb 28, 2024 | 8-K Item 2.02 (results) | — |
| Nov 7, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on QURE
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.